Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Journal of Crohn'S & Colitis|August 17, 2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised TrialSéverine Vermeire, Geert D'Haens, Filip Baert, et al.
Acta Gastro-Enterologica Belgica|March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitisGert Van Assche, Filip Baert, Marc De Reuck, et al.
United European Gastroenterology Journal|November 9, 2019
Beclomethasone dipropionate in microscopic colitis: Results of an exploratory open-label multicentre study (COLCO)Thomas De Corte, Emilie Janssens, Ann D'Hondt, et al.
Gastrointestinal Endoscopy|October 9, 2004
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDMarco Daperno, Geert D'Haens, Gert Van Assche, et al.
Gut|July 13, 2017
Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trialRaf Bisschops, Talat Bessissow, Joseph A Joseph, et al.
Pharmacogenetics and Genomics|March 26, 2009
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximabCharlotte Magdelaine-Beuzelin, Séverine Vermeire, Margaret Goodall, et al.
The Lancet. Gastroenterology & Hepatology|October 30, 2025
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort studyGeert R D'Haens, Mark Löwenberg, Filip Baert, et al.
Inflammatory Bowel Diseases|March 30, 2021
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel DiseasesClaire Liefferinckx, Jérémie Bottieau, Jean-François Toubeau, et al.
Journal of Crohn'S & Colitis|October 3, 2022
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position PaperJurij Hanzel, Peter Bossuyt, Valerie Pittet, et al.
Journal of Crohn'S & Colitis|February 13, 2025
A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel diseaseAnneline Cremer, Nicolas Rosewick, Maxfield Kelsey, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Journal of Crohn'S & Colitis|August 17, 2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised TrialSéverine Vermeire, Geert D'Haens, Filip Baert, et al.
Acta Gastro-Enterologica Belgica|March 7, 2003
The role of aminosalicylates in the treatment of ulcerative colitisGert Van Assche, Filip Baert, Marc De Reuck, et al.
United European Gastroenterology Journal|November 9, 2019
Beclomethasone dipropionate in microscopic colitis: Results of an exploratory open-label multicentre study (COLCO)Thomas De Corte, Emilie Janssens, Ann D'Hondt, et al.
Gastrointestinal Endoscopy|October 9, 2004
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDMarco Daperno, Geert D'Haens, Gert Van Assche, et al.
Gut|July 13, 2017
Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trialRaf Bisschops, Talat Bessissow, Joseph A Joseph, et al.
Pharmacogenetics and Genomics|March 26, 2009
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximabCharlotte Magdelaine-Beuzelin, Séverine Vermeire, Margaret Goodall, et al.
The Lancet. Gastroenterology & Hepatology|October 30, 2025
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort studyGeert R D'Haens, Mark Löwenberg, Filip Baert, et al.
Inflammatory Bowel Diseases|March 30, 2021
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel DiseasesClaire Liefferinckx, Jérémie Bottieau, Jean-François Toubeau, et al.
Journal of Crohn'S & Colitis|October 3, 2022
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position PaperJurij Hanzel, Peter Bossuyt, Valerie Pittet, et al.
Journal of Crohn'S & Colitis|February 13, 2025
A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel diseaseAnneline Cremer, Nicolas Rosewick, Maxfield Kelsey, et al.
Pageof 10